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Abstract 
 
 
Background:  The transmission through contacts among MSM (men who have sex with men) is one of the 
dominating contributors to HIV prevalence in industrialized countries. In Amsterdam, the capital of the 
Netherlands, the MSM risk group has been traced for decades. This has motivated studies which provide 
detailed information about MSM’s risk behavior statistically, psychologically and sociologically.  Despite the 
era 
of potent antiretroviral therapy, the incidence of HIV among MSM increases. In the long term the contradictory 
effects of risk behavior and effective therapy are still poorly understood. 
Methods:  Using a previously presented Complex Agent Network model, we describe steady and casual 
partnerships to predict the HIV spreading among MSM. Behavior-related parameters and values, inferred from 
studies on Amsterdam MSM, are fed into the model; we validate the model  using historical yearly incidence 
data. Subsequently, we study scenarios to assess the contradictory  effects of risk behavior and effective 
therapy, by varying corresponding values of parameters. Finally, we conduct quantitative analysis based on the 
resulting incidence data. 
Results:  The simulated incidence reproduces the ACS historical incidence well and helps to predict the HIV 
epidemic among MSM in Amsterdam. Our results show that in the long run the positive influence of effective 
therapy  can be outweighed  by an increase in risk behavior of at least 30% for MSM. 
Conclusion:  We recommend, based on the model  predictions, that lowering risk behavior is the 
prominent control mechanism of HIV incidence even in the presence of effective therapy. 
 
 
 
 
 
 
 
Background 
The HIV epidemic is a global challenge and has a destructive impact on human life and welfare. One of the 
major or even dominating contributors to HIV prevalence in industrialized countries is the transmission 
through contacts among men who have sex with men (MSM). Particularly, in the Netherlands, MSM still 
accounts for the highest incidence of Sexually Transmitted Infections (STIs) including HIV [1]. In fact, the 
proportion of MSM in new HIV cases recorded at the HIV registry continued to increase from 44% in 2003 
to 59% in 2006 [1, 2]. 
Amsterdam harbors the majority of the largest MSM risk group in the Netherlands that has been traced 
 
 
 
 
 
and recorded for decades, providing  us with detailed information about Amsterdam MSM’s behavior 
characteristics. The Amsterdam Cohort Study (ACS) is such a study which has been conducted since 1984 
with thousands of MSM recruited. 
In order to embody heterogeneous behavior such as personal infection progressions and steady/casual 
partnership linkages, we use agent-based modeling  to simulate the HIV spreading among MSM in 
Amsterdam, based on a previously presented Complex Agent Network model [3]. This model helps to 
describe partnerships in detail, with (steady or casual) partnerships, durations and frequencies of sexual 
actions, influencing the HIV spreading among MSM in a well-structured in silico population. This 
enables modeling  realistically  heterogeneous populations and incorporation of social behavior data in the 
model. Risk behavior is of vital significance to HIV transmission and has sparked many psychological 
surveys. Questionnaires completed by 324 MSM aged 18-34 were conducted  by Davidovich  et al., to assess 
sexual behavior and related cognitions [4]. The results reveal, amongst others, that unprotected anal 
intercourse (UAI) is regarded as a symbol of trust and believing that the partner desires UAI is associated 
with less condom use; additionally, perceiving UAI as more gratifying was associated with having riskier 
UAI. Unfortunately, beliefs of people living with HIV about their own responsibility for preventing HIV 
transmission (personal responsibility)  and their sex partners’ responsibility  for protecting themselves 
(partner responsibility)  are poorly understood [5]. 
Despite psychological and sociological reasons, the so-called “safer sex fatigue” and excessive confidence in 
low viral load further intensify the reluctance on reducing risky behavior. Crepaz et al., concluded [6] that 
people’s beliefs about Highly Active Antiretroviral Therapies (HAART) and viral load may promote 
unprotected sex, although HIV-positive patients receiving HAART did not exhibit increased sexual risk 
behavior, even when therapy achieved an undetectable viral load. In Amsterdam, the worrying increase of 
STIs was investigated in studies carried out by the department of AIDS research of the municipal health 
service. The result indicated that the introduction of HAART may have had an influence on the increase of 
STIs and risky sexual behavior [7]. 
Increase in risk behavior and resurgent epidemics have been reported post-HAART,  and resurgent 
epidemics is most likely caused by increasing sexual risk behavior [8]. Furthermore, low diagnosis 
fraction of infections may intensify this threat, since HIV-positive men who are unaware of their 
serostatus have higher risk behavior than the aware group [9ffi11]. Regarding the ACS, only 40% MSM 
accepted HIV testing at their STI consultation, among the recently infected at the STI clinic [12]. 
In this study, the primary objective is to explain  and reproduce  historical  data and then assess the 
 
 
 
 
 
potential influence of varying risk behavior and therapy factors, with the aim to understand and predict 
the HIV spreading among MSM in Amsterdam. For this we need to combine sexual contact networks with 
HIV infection dynamics and individual behavior. To the best of our knowledge this is the first report on 
this combined  evidence-based computational  epidemics model. 
 
 
Methods 
Modeling  the  HIV epidemic in Complex  Agent  Networks 
Using a previously developed Complex Agent Network [3], we model the HIV epidemics among MSM in 
Amsterdam through a sexual contact network in which each node represents an individual  and edges 
represent potentially infectious contacts. Please see Fig. 2 in [13] as a schematic illustration of virus 
spreading in a network. The number of edges emanating from a node is the degree of the node and the 
degree distribution  is the distribution of this quantity across the population [14]. In this study, the degree 
of a node, drawn from a specific degree distribution, is assumed to be static while the neighboring nodes 
that this node links to may change over time. There are classes of network geometry such as small-world, 
Poisson and scale-free networks. Since scale-free networks have been shown to be the representative of a 
variety of human sexual contact networks [15ffi17], we perform stochastic simulations  of the spreading of 
HIV in undirected scale-free networks. The scale-free networks are characterized by a highly skewed 
distribution of contacts so that most of the nodes are weakly connected and a small number of nodes have 
very high connectivity. In particular,  the degree distribution of this class of networks follows a power law 
distribution,  i.e., pk  = Ak
−γ  where A is a normalization factor. After each node is assigned with a degree 
drawn from a given power law, these nodes are connected at random according to the so-called confi
guration model [18, 19] with the guarantee that the sum of all degrees is an even number and that there 
are no loops (nodes connected to themselves) and multiple  edges (between two nodes). 
The disease status of infected individuals is heterogenous with respects  to infection stages, disease 
durations and infectiousness, etc., so that we can model individuals  as agents and individuals’  status 
transitions as internal changes of agents. The HIV infection progression occurs in roughly three stages: 
primary infection (PI), asymptomatic period (AP) and AIDS. Regarding status transition, for instance, 
infection reaches from PI to AP with a delay of about 3 months. We assume an irreversible “negative ⇀ PI 
⇀ AP ⇀ AIDS” transition order for each infection, excluding the case that an individual  with AIDS can 
with the right treatment go back to the asymptomatic  phase, because in general patients are most likely 
diagnosed and treated before reaching the AIDS stage. During the HIV epidemic, each individual’s 
 
 
 
 
 
infection status is related to temporally varying infectiousness due to the corresponding different plasma 
HIV RNA levels. The transmission probability  across each edge depends on the status of the two 
connected individuals.  Therefore, the probability  with which a susceptible individual  becomes infected is 
determined by the connectivity  (degree) of the individual and the infection status of his partners 
(neighboring nodes) in the network. For simplicity,  we assume no HIV mutations during the course of HIV 
epidemic. Additionally, individuals who die of AIDS will be replaced by healthy individuals, keeping the 
total of MSM under study static throughout simulations. 
Our model distinguishes between steady and casual relationships as two types of sexual relationships, which 
brings different transmission probabilities that occur across likewise steady or casual edges. Results from 
previous models show that the transmission dynamics of HIV differ significantly depending on 
relationship type, i.e., long steady relationships or short casual partnerships [20]. Moreover, there are 
strong indications that a substantial proportion of new HIV infections occur within steady partnerships 
[20, 21]. Multiple sexual actions can take place along a steady edge (within a steady relationship) yearly, 
while only one sexual action take place along a casual edge (within a casual partnership) yearly. Each 
individual can have at most one steady partner with whom he stays for some time. Casual partnerships 
can be formed between any two individuals, but men with a steady partner have fewer partners than 
single men. Even steady partners may be involved in casual partnerships during or between steady 
relationships, though they may negotiate safety agreements to be monogamous or to have no UAI outside 
the relationship. Considering 
two partners with one infected and the other susceptible, the number of sexual acts that they have within a 
specified time duration, together with the infected one’s infectiousness and therapy effect, the susceptible 
one’s susceptibility, and risk behavior involving the two, determines the transmission probability  from the 
infected one to the susceptible one across their partnership  edge (see Section 3.3 in [3] for  details). 
 
 
Estimating parameters 
Based on the Amsterdam cohort study (ACS) and literature, we estimate the sociological, virological and 
medical values and distributions of important  parameters, and these are as listed in Table 1. The ACS of 
HIV infection and AIDS among MSM living in Amsterdam was initiated in 1984 and has involved  2299 
men until 2006 [22]. Of the 2299 MSM, 571 were HIV-positive at study entry and 192 seroconverted during 
follow-up until the end of 2006. Consequently,  characteristics  of MSM’s behavior and surveyed yearly HIV 
incidence over calendar years for the population are reported periodically  [23]. How parameters in Table 1 
are fed into the model and affect the infection probability  between a HIV-positive and a HIV-negative are 
 
 
 
 
 
explicitly explained in Sec. 3.3 and 5.2.2 in [3]. Specifically, the infection probability per sexual action is 
computed by multiplying a multi-year statistic of transmission probability  per action and several coeffi
cients indicating,  e.g., personal infectivity  reduction due to treatment, personal infectivity increases due 
to risky behavior, and reduction of transmission probability  between two steady partners if they reach a 
safety agreement on having no contacts outside the relationship. 
 
 
Designing scenarios for predicting the  HIV epidemic 
The model can be used to predict the HIV epidemic by tuning the parameters related to two important 
factors: therapy effectiveness and risk behavior. Ref. [3] provides the value for the risk behavior factor in 
1985-2005 among people infected  and people not infected  with  HIV. It is strongly believed that risk 
behavior decreased until 1996 because of fear of the harm of HIV. The introdction of HAART in 1996 was 
associated with a slow increase in risk behavior. To investigate the counterbalancing impact of therapy 
effectiveness and risk behavior, we design several scenarios as listed in Table 2 to tentatively predict the 
HIV epidemic among a fixed number of 2299 individuals  which is the total of MSM involved in ACS 
substudies since 1984. A reference scenario uses default values of parameters (Table 1) which remain 
unchanged during the course of simulations.  Prediction  scenarios 1-5 are designed based on various 
combinations of therapy reduction and risk behavior factors. We perform stochastic simulations of these 
scenarios from 1985 to 2044 (initialized  according to the situation in 1984) with 1-year time steps and 
compare the results of the prediction scenarios to that of the reference scenario, with the aim to evaluate 
the significance of the factors. Each simulation result is an average over 30 realizations. 
 
 
Results 
Reference scenario 
The incidence resulting from the reference scenario (RS in Table 2) simulation (1985-2020) versus the ACS 
historical  incidence  data (1985-2006) is shown in Figure 1. The curve of the simulated incidence is fl
uctuating less intensively  compared to that of the ACS historical data. This is most likely due to the fact 
that the ACS has traces and records in incomprehensive  populations  every year (e.g., 2 HIV positives out 
of 511.12 in 1988 and 5 out of 374.54 in 2002, see Table 5 in [23]) while we model the HIV epidemic in a 
population with a fixed size of 2299. 
Compared to 1.66 in 2006, the RS incidence does not change noticeably at the time steps following 2006. 
For example, the incidence increases to 1.69 in 2015 and 1.74 in 2020, and then declining  to 1.63 in 2030 
 
 
 
 
 
 
Table 1: The values or  distributions of parameters (partly) for  modeling the HIV epidemic. 
 
Parameter Value Description Source 
Duration of steady 
The duration of steady partnerships among 
1 
relationships 
DU (1, 2) Amsterdam MSM is reported to have an [20]
 
expected value of 1.5 years. 
Duration of the 
asymptomatic stage for the B(26, 0.5)2 
This stage lasts 13 years for people with a 
[24, 25] 
untreated 
failed treatment or without any therapy.
 
This stage lasts a mean value of 22.5 years for 
Duration of the people with a successful treatment. And the 
asymptomatic stage for the B(52, 0.5) duration is likely increased to a mean value of [26ffi28] 
successfully treated 26 years, thanks to the wide use of HAART 
and the improvement in the therapy regimens. 
Frequency of sexual actions 
per year between steady 3  The frequency of either URAI or UIAI 
partners (with infected at 
P (30) 
between steady partners is 15 per year. 
[20]
 
stage AP) 
Frequency of sexual actions The PI stage lasts for about 3 months which 
between steady partners in is shorter than the 1-year time step, so that 
the first 3 months and the we divide individuals’  first year of infection [20] 
last 9 months,  respectively  
P (8) & P (22)  
into two periods. Thus, the frequencies in 
(with infected at stage PI) these two periods adds up to 30. 
Transmission probability 
per URAI/UIAI4   act (with 0.22/0.044 [29ffi31] 
infected at stage PI) 
Transmission probability The infected in the last 9 months of PI 
per URAI/UIAI act (with contribute the same to transmission [29ffi31] 
infected at stage AP)  
0.011/0.0022 
possibility  per act as they do at stage AP. 
Reduction in risky behavior Men may make an agreement with his steady 
along casual partnerships  partner to be monogamous or to have no UAI see Sec. 2 
for men who have a steady 
0.84 
outside the relationship, leading to less risky in [20] 
partner behavior. 
Moderate (default) 
treatment-induced CU (0.1, 0.5)6 
ART can moderately reduce transmission 
[32] 
infectivity reduction factor5 
probability by 50-90%.
 
Optimistic 
ART can optimistically  reduce transmission 
treatment-induced [32] 
infectivity reduction factor 
CU (0.01, 0.1) probability by 90-100%.
 
Initial population size 2299 
People involved in all substudies add up to 
2299. 
[22]
 
The power-law degree MSM population follows a power-law degree 
distribution’s exponent γ in 1.6 distribution  with a value of γ in the interval [17] 
this study between 1.5 and 2. 
The power-law degree 
distribution’s maximum 200 We assume so. 
degree kmax 
The fraction of vertices  We assume that a small portion in a 
with a degree of 0 
0.01 
population not having any contact. 
 
1 DU (val1, val2) is a discrete uniform distribution with  val1 and  val2 as the  lower and  upper  bounds. 
2 B(n, p) is a binomial distribution. 
3 P(λ) is a Poisson distribution. 
4 URAI, unprotected receptive anal  intercourse; UIAI,  unprotected insertive anal  intercourse. 
5 Those who  are  receiving treatment  can  obtain an  reduction in  infectivity and  thus decrease  transmission probability 
per act.   The  untreated’s infectivity remains on baseline quantities given  in [29–31]. 
6
 
CU (val1, val2) is a continuous uniform distribution with  val1 and  val2 as the  lower and  upper bounds. 
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Table 2:   Scenarios  for   simulating the  HIV  epidemic  among  MSM  in   Amsterdam  (factors 
changed since 2006). The values of parameters change from 2006 onward  in the simulations of scenarios. 
The risk behavior factor is a multiplicative factor of the transmission probability between two partners. For 
prediction scenarios, the value of the risk behavior factor is calculated by scaling the value in 2000-2005 (1.30 
for both the HIV negative and positive, see Table 2 in [3]) to account for the increase in risk behavior after 
2006. For example, an increase of 5% in risk behavior is assumed after 2006 for P1. The distributions of the 
moderate and optimistic treatment-induced infectivity reduction factors are listed in Table 1. All scenarios 
take a value of moderate treatment-induced  infectivity  reduction from 1985 to 2006. 
 
Scenario Risk behavior factor Treatment-induced  infectivity  reduction factor 
Reference (RS) 1.30 Moderate 
Prediction  1 (P1) 1.05*1.30 Moderate 
Prediction  2 (P2) 1.05*1.30 Optimistic 
Prediction  3 (P3) 1.10*1.30 Optimistic 
Prediction  4 (P4) 1.20*1.30 Optimistic 
Prediction  5 (P5) 1.30*1.30 Optimistic 
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Figure 1:  The incidence resulting from the RS   simulation (solid) versus the  ACS  historical 
incidence data (dashed).  The RS is simulated  using default parameter values (Table 1) that 
remain unchanged throughout. 
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and 1.60 in 2040 (as shown in Figure 2b). 
 
 
Model  validation 
To validate our model, a paired-sample T-test is computed, comparing the simulated incidence of RS and 
the ACS historical incidence in 1985-2006. The null-hypothesis under consideration is that there is no diff
erence between these two series of data with a significance level of 0.05 (data not shown). Meanwhile, we 
believe that the resulting validity also applies to the testing for all the prediction scenarios that share 
identical parameter setting to that of RS in the range of years of 1985-2006 (see Figure  2a). 
 
 
Prediction scenarios 
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(a)   The  simulated incidence of the  scenarios (1985-2020) and  the 
ACS  historical incidence (1985-2006) 
(b)   The  simulated incidence of the  scenarios (2005-2044) 
 
Figure  2: Simulated incidence resulting from scenarios. 
 
The incidence resulting from prediction scenarios, together with the RS incidence and ACS historical 
incidence, is shown in Figure 2. To further  compare these data and assess the effect of parameter tuning, 
we list the simulated incidence and the corresponding increase or decline percentage in each specified 
year for predicting scenarios compared to the RS incidence in Table 3. 
The P1 incidence is higher in each specified year than the RS incidence though a moderate 
treatment-induced infectivity reduction factor is adopted in both simulations. We observe an increases of 
10.95% in 2030 and of 2.87% in 2040, respectively. 
Once the optimistic therapy is adopted in the following P2-P4 simulations, the resulting incidence shows 
an obvious overall downtrend compared to the RS incidence, since down arrows are predominantly  present 
 
 
 
 
 
in the P2, P3 and P4 columns of Table 3. Among incidence resulting from these 3 simulations,  the P2 
incidence declines to the largest extent, e.g., by 11.24% in 2030 and 28.7% in 2040. 
Surprisingly, for the P5 simulation an overall uptrend occurs compared to the RS incidence, since up 
arrows are predominantly  present in the P5 column of Table 3. Although the optimistic treatment-induced 
infectivity reduction factor is used for all P2-P5 simulations, the P5 incidence shows a totally different 
upgoing trend compared to the largely downgoing incidence resulting from the P2, P3 and P4 simulations 
in the long run. For example, in 2035 there is a 5.5%↑ for P5 incidence, while there are 26.3%↓, 10.7%↓ 
and 9.63%↓ for P2, P3 and P4 incidence, respectively. Additionally, from 2030 onward  the P5 incidence 
approximately  remains more or less at the same level as the RS incidence, for instance, 1.64 versus 1.63 in 
2030 and 1.58 versus 1.60 in 2040, respectively. 
In addition, the yearly fraction of the diagnosed (the number of the diagnosed divided by the number of 
the infected), inferred from our simulated results, is fluctuating within the range of 0.35-0.56 and finally 
approaching  0.41 (data not shown). 
 
 
Table 3:  Resulting  incidence from simulations of  scenarios.  Data points of incidence, taken at 5- 
year intervals  after 2005 from the results of scenarios simulations,  are listed and compared.  In each year 
the incidence resulting from every prediction scenario is compared percentagewise to that of the 
reference scenario (*), respectively. 
 
Year 
Simulated incidence 
RS∗ P1 P2 P3 P4 P5 
2010 
1.61423 1.76164 1.62148 1.7568 1.8583 2.18211 
- 9.13% ↑ 0.45% ↑ 8.83% ↑ 15.12% ↑ 35.18% ↑ 
2015 
1.69397 1.77855 1.68189 1.75922 1.87763 2.15311 
- 4.99% ↑ 0.71% ↓ 3.85% ↑ 10.84% ↑ 27.1% ↑ 
2020 
1.73505 1.79063 1.50065 1.56831 1.84138 2.0057 
- 3.2% ↑ 13.51% ↓ 9.61% ↓ 6.13% ↑ 15.6% ↑ 
2025 
1.60215 1.77855 1.54657 1.57556 1.59248 1.71331 
- 11.01% ↑ 3.47% ↓ 1.66% ↓ 0.6% ↓ 6.94% ↑ 
2030 
1.63356 1.81238 1.44991 1.40399 1.52482 1.64081 
- 10.95% ↑ 11.24% ↓ 14.05% ↓ 6.66% ↓ 0.44% ↑ 
2035 
1.5804 1.76647 1.16476 1.41124 1.42816 1.66739 
- 11.77% ↑ 26.3% ↓ 10.7% ↓ 9.63% ↓ 5.5 % ↑ 
2040 
1.59973 1.64564 1.14059 1.3025 1.37016 1.57556 
- 2.87% ↑ 28.7% ↓ 18.58% ↓ 14.35% ↓ 1.51 % ↓ 
 
 
 
Discussion 
We construct an agent-based probabilistic Complex Agent Network model to gain increased insight 
into the spread of HIV among men who have sex with men in Amsterdam. In our approach, the in 
silico 
 
 
 
 
 
population is mimicked as sexual contact networks and the transmission dynamics of HIV is embedded in 
those networks describing complex interactions among MSM. Sexual contacts, steady or casual, between 
each pair of partners that have individual  disease status, contribute  to virus transmission from the infected 
to the susceptible. The simulated incidence in 1985-2006 is able to reproduce the ACS historical incidence 
well (Figure 1 and Figure 2a), based on the null-hypothesis  T-test performed. We examine how two factors 
of vital significanceffithe treatment-induced infectivity reduction factor and risk behavior factorffiinfluence 
the HIV spreading by performing a set of scenario simulations.  The resulting analyses (Table 3) reveal that 
in the long term the effects of the optimistic therapy can be counterbalanced by an increase in risk 
behavior of at least 30% for MSM. This is in line with the conclusion drawn by Wilson et al., that the risk 
of HIV transmission in male homosexual partnerships is high over repeated exposures even in the presence 
of effective treatment [33]. 
Our research takes advantage of the statistical details of MSM’s behavior obtained from the ACS, showing 
a promising way of simulating HIV spreading among a specific group of people. In contrast, many other 
modeling studies were not able to incorporate this kind of detailed data. This study provides an alternative 
and reliable approach to model virus spreading in a highly connected population with individual  details. 
The yearly fraction of the diagnosed is relatively low, restricting the positive influence of highly effective 
therapy. This low value is consistent with what has been observed in reality. For example, Xiridou et al., 
stated that 42% of the infected people at the asymptomatic stage know they are HIV positive 
(diagnosed) [20]; Gras et al., concluded that observed annual proportions of diagnoses for homosexual 
men were decreasing from about 57% in 1996 to 42% in 2004 taking into account all data in 1996-2004, or 
approximately  remaining at 44% taking into account data in 2000-2004  [34]. Accordingly, many infected 
people are unaware of their infection due to low fraction of diagnosis and thereby will not benefit from 
highly effective therapy.  Extreme preventive  measures have been proposed such as universal testing 
followed by immediate treatment [35]. But this approach is not practical, as annual universal testing is a 
logistical challenge and immediate treatment regardless of CD4 count is not in line with current treatment 
guidelines. Policy makers therefore consider much more subtle and realistic countermeasures. 
The simulations demonstrates that the incidence varies in different time points (Figure 2). We believe that 
this sort of rapid fluctuations in incidence is inherent and is likely the result of network structures in 
combination with the stochastic nature of the models. 
More precise data is needed to estimate the infectiousness of people who are receiving therapy, taking into 
consideration their adherence, behavior changes since receiving therapy and rates of resistance emergence. 
 
 
 
 
 
Also, a better model of estimating risk behavior is expected to further improve our understanding of the 
underlying determinants of risk behavior. For example, the fraction of MSM that use condoms without any 
exception or only during the last insertive anal intercourse can be introduced. 
The transmission model has several challenges. Firstly, the model is validated by comparing the simulated 
yearly incidence to the ACS historical incidence, ignoring prevalence and other indicators. This is mainly 
due to the availability of the ACS incidence data, and also the the dimensionless feature of the incidence 
since the number of recruited MSM in the ACS varies each year while the network size remains constant 
throughout. To avoid a possible bias resulting from this incidence-biased process, we can supplement 
comparisons according to indicators other than incidence. 
Secondly, for practicability,  we assume that HAART can to an optimistic extent reduce patients’ 
infectiousness by up to 99% instead of 100%. There exists a serious controversy  on the effectiveness of 
HAART. Although HAART could reduce viral load to an undetectable level, Edwin J Bernard stated that 
being undetectable does not necessarily mean being entirely uninfectious [36]. Additionally, quantifying the 
proportion of people who will reach undetectable viral load due to therapy still relies on further clinical 
surveillance and statistics. 
The advantages of using the Complex Agent Network model have not been fully exploited in this study; for 
example we use neither an individually  dynamic risk behavior factor nor consider individual  histories of 
risky contact (due to the lack of data). Incorporating more data-driven details may result in dramatic 
increases in computational cost to which modeling a population in hierarchical networks can be a 
promising solution [37]. 
 
 
Conclusion 
Our results suggest that the positive influence of effective therapy can be outweighed by an increase in risk 
behavior of at least 30% for MSM. This implies that if universal voluntary HIV testing is currently 
impossible or impractical, lowering risk behavior is the prominent control mechanism of HIV incidence 
even in the presence of effective treatment. This is an essential result since recent studies indicate that 
even in the presence of potent antiretroviral  therapy, the incidence of HIV among MSM still increases. 
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